La Jolla, CA, United States of America

Florian Sulzmaier

USPTO Granted Patents = 4 

Average Co-Inventor Count = 5.8

ph-index = 1


Location History:

  • La Jolla, CA (US) (2021 - 2024)
  • San Diego, CA (US) (2024)

Company Filing History:


Years Active: 2021-2024

Loading Chart...
4 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Florian Sulzmaier

Introduction

Florian Sulzmaier is a notable inventor based in La Jolla, California, recognized for his significant contributions to the field of biotechnology. With a total of four patents to his name, he has made strides in developing therapeutic solutions for various diseases, particularly in cancer treatment.

Latest Patents

Among his latest patents, Sulzmaier has developed OX40-binding polypeptides and their uses. These innovations include VHH-containing polypeptides that bind OX40, with some embodiments designed to agonize this target. Additionally, he has created binding polypeptides that specifically target PD-1, which are crucial for therapeutic compositions aimed at treating cancer. These include fusion proteins and chimeric antigen receptors, along with pharmaceutical compositions that utilize these polypeptides.

Career Highlights

Throughout his career, Florian Sulzmaier has worked with prominent companies in the biotechnology sector, including Inhibrx, Inc. and Inhibex, Inc. His work has been instrumental in advancing therapeutic strategies that leverage his patented technologies.

Collaborations

Sulzmaier has collaborated with notable professionals in his field, including John C. Timmer and Brendan P. Eckelman. These partnerships have further enhanced the impact of his innovations in biotechnology.

Conclusion

Florian Sulzmaier's contributions to biotechnology through his patents and collaborations highlight his role as a leading inventor in the field. His work continues to pave the way for advancements in cancer treatment and therapeutic development.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…